신풍제약

019170KOSPI

48.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40

News Sentiment12.5 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 6.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Shinpoong Pharmaceutical is enhancing its competitiveness in the highly competitive domestic pharmaceutical market through global new drug development, improved generics, and first-generic launches, while focusing investments on high-profit products to improve profitability. Although sales increased by approximately 10.42% compared to the previous period, the company still recorded an operating loss due to ongoing R&D expenses.

Number of Employees

792people

Average Salary

77.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

53.86Industry Average 15.000.0Point

3.6x industry avg (risky)

PBR

1.67Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

3.17Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

5.48Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲113.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 8,620Won52-week high 15,69052-week low 7,210

1-month return2.0Point

1m -6.71% (slight drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral투자판단관련주요경영사항 (급성 허혈성 뇌졸중 치료제 SP8203 임상 3상 시험변경계획 승인)2026-10-22